Breaking News

Andelyn Biosciences Selected to Manufacture AAV Gene Therapy for Rare NKH Disorder

Will apply the AAV Curator Platform to manufacture clinical grade AAV for Drake Rayden Foundation for the treatment of nonketotic hyperglycinemia.

Author Image

By: Charlie Sternberg

Associate Editor

Andelyn Biosciences Inc., a cell and gene therapy Contract Development and Manufacturing Organization (CDMO), has been selected by Drake Rayden Foundation to apply the AAV Curator Platform to manufacture clinical grade AAV for the Treatment of Nonketotic Hyperglycinemia (NKH), a rare, inherited metabolic genetic disorder caused by a mutation in the GLDC gene. Andelyn will work closely with the Drake Rayden Foundation and scientists from Dr. Steven Gray’s laboratory at the University of Texas ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters